385 results on '"Wang, Liang‐Yen"'
Search Results
2. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
3. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1
4. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
5. Tumor Necrosis Factor-α Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection
6. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma
7. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study
8. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients
9. Human Leukocyte Antigen Class I and II Alleles and Response to Interferon-α Treatment, in Taiwanese Patients with Chronic Hepatitis C Virus Infection
10. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles
11. Comparison of Clinical Application of the Abbott HBV PCR Kit and the Versant HBV DNA 3.0 Test to Measure Serum Hepatitis B Virus DNA in Taiwanese Patients
12. Hepatocellular Carcinoma Associated With Liver Abscess
13. HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study
14. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma
15. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy
16. Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C
17. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
18. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection
19. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B
20. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
21. Qualitative Application of COBAS AMPLICOR HCV Test Version 2.0 Assays in Patients with Chronic Hepatitis C Virus Infection and Comparison of Clinical Performance with Version 1.0
22. Prevalence and Clinical Significance of SEN Virus Infection Among Volunteer Blood Donors in Southern Taiwan
23. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin
24. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy
25. Polymorphism of interferon–gamma gene at position +874 and clinical characteristics of chronic hepatitis C
26. Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors
27. Sex differences in relation to serum hepatitis B e antigen and alanine aminotransferase levels among asymptomatic hepatitis B surface antigen carriers
28. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
29. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response
30. Polymorphisms in the interferon-γ gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-α and ribavirin
31. Independent and additive interactive effects among tumor necrosis factor-(alpha) polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma
32. Reappraisal of the Characteristics of Glucose Abnormalities in Patients With Chronic Hepatitis C Infection
33. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
34. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation
35. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication
36. The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies
37. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients
38. A 24-week course of high-dose interferon-α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels
39. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy
40. A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan
41. Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique
42. Incidence and Clinical Significance of Spontaneous Intrahepatic Portosystemic Venous Shunts Detected by Sonography in Adults without Potential Cause
43. The role of hepatitis C virus in chronic hepatitis B virus infection
44. Tumor necrosis factor-[alpha] promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection
45. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors
46. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-α monotherapy in Taiwan
47. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study: APASL\Abstract\124
48. The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin
49. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors
50. Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.